Plain-English translation of NCT05319639 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination treatment for advanced stomach cancer that cannot be surgically removed. The combination includes chemotherapy drugs (, , , and with Leucovorin) plus an immunotherapy medication called . The study is designed to find the safest and most effective doses of these medications when given together.
Advanced stomach cancer is very difficult to treat, and patients need better treatment options. This trial is exploring whether combining traditional chemotherapy with an immune-boosting medication might work better than chemotherapy alone by helping the body's own immune system fight the cancer.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the chemotherapy combination every 14 days, with doses gradually increasing over time as the study determines safe levels. The chemotherapy infusions include a 46-hour continuous pump infusion that you can do at home with a portable pump. You would also receive an immunotherapy injection every 14 days. The study involves close monitoring with blood tests and doctor visits to watch for side effects and measure how well the treatment is working.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Fujian Cancer Hospital
Enrollment target
~51 participants
Started
February 2023
Primary completion
October 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
lin rong bo, bachelor
Fujian Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.